
First published in the *Government Gazette*, Electronic Edition, on 31 December 2021 at 12 noon.

No. S 1076

HEALTH PRODUCTS ACT (CHAPTER 122D)

HEALTH PRODUCTS (CELL, TISSUE AND GENE THERAPY PRODUCTS) (AMENDMENT) REGULATIONS 2021

In exercise of the powers conferred by section 72(1) of the Health Products Act, the Health Sciences Authority, with the approval of the Minister for Health, makes the following Regulations:

Citation and commencement

1. These Regulations are the Health Products (Cell, Tissue and Gene Therapy Products) (Amendment) Regulations 2021 and come into operation on 3 January 2022.

Amendment of regulation 2

2. Regulation 2(1) of the Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (G.N. No. S 104/2021) is amended —

(a) by deleting the definition of “healthcare institution licence” and substituting the following definition:

““healthcare institution licence” means —

(a) a licence granted under the Healthcare Services Act 2020 for the provision of any licensable healthcare service; or

(b) a licence issued for a healthcare institution under the Private Hospitals and Medical Clinics Act 1980;” and

(b) by deleting the definition of “licensed healthcare institution” and substituting the following definition:

““licensed healthcare institution” means —

- (a) any premises or conveyance specified in a licence granted under the Healthcare Services Act 2020 for the provision of any licensable healthcare service; or
- (b) a healthcare institution that is licensed under the Private Hospitals and Medical Clinics Act 1980;”.

Made on 30 December 2021.

BENJAMIN ONG
Chairman,
Health Sciences Authority,
Singapore.

[401:04/01-000; AG/LEGIS/SL/122D/2020/13 Vol. 1]

(To be presented to Parliament under section 72(5) of the Health Products Act).